Global Clinical Trials Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Clinical Trials Market is presumed to reach the market size of nearly USD 159.29 Billion by 2032 from USD 85.49 Billion in 2023 with a CAGR of 7.16% under the study period 2024-2032.

The clinical trials are the research investigation that finds new ways to prevent, diagnose or treat disease. It's the final step in a long process. Where new drugs, new approaches to surgery or radiation therapy, and advances in new areas such as gene therapy is investigated. Testing of treatment or drug is done in steps called phases.

MARKET DYNAMICS

The growing prevalence of diseases along with the rising incidence of new diseases is driving market growth. Also, increasing investments on new product development, such as personalized medicine and evolution in technology in emerging countries is fuelling market growth. However, budget constraints of small and medium-sized pharmaceutical and biotechnology companies are expected to restrain the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Clinical Trials. The growth and trends of Clinical Trials industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Clinical Trials market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Phase

Phase I
Phase II
Phase III
Phase IV

By Study Design

Autoimmune/Inflammation
Pain Management
Oncology
CNS Condition
Diabetes
Obesity
Cardiovascular
Others

By Indication

Autoimmune/Inflammation (Rheumatoid arthritis, Multiple Sclerosis, Osteoarthritis, Irritable Bowel Syndrome (IBS), Others)
Pain Management (Chronic Pain, Acute Pain)
Oncology (Blood Cancer, Solid Tumors, Other)
CNS Condition (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Others)
Diabetes
Obesity
Cardiovascular
Others

By Sponsor

Pharmaceutical & Biopharmaceutical Companies
Medical Device Companies
Others

By Service Type

Protocol Designing
Site Identification
Patient Recruitment
Laboratory Services
Bioanalytical Testing Services
Clinical Trial Data Management Services
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Trials market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Trials market include Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.), ICON Plc, Charles River Laboratories International Inc., IQVIA, Syneos Health, SGS SA, Parexel International Corporation, Wuxi AppTec Inc, Chiltern International Ltd (Laboratory Corporation Of America), Eli Lilly And Company, Novo Nordisk A/S, Pfizer, Clinipace (Caidya). This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR11210536

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CLINICAL TRIALS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Phase
- 3.7.2 Market Attractiveness Analysis By Study Design
- 3.7.3 Market Attractiveness Analysis By Indication
- 3.7.4 Market Attractiveness Analysis By Sponsor
- 3.7.5 Market Attractiveness Analysis By Service Type
- 3.7.6 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY PHASE

5.1. Overview By Phase
5.2. Historical and Forecast Data Analysis By Phase
5.3. Phase I Historic and Forecast Sales By Regions
5.4. Phase II Historic and Forecast Sales By Regions
5.5. Phase III Historic and Forecast Sales By Regions
5.6. Phase IV Historic and Forecast Sales By Regions

6. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY STUDY DESIGN

6.1. Overview By Study Design
6.2. Historical and Forecast Data Analysis By Study Design
6.3. Autoimmune/Inflammation Historic and Forecast Sales By Regions
6.4. Pain Management Historic and Forecast Sales By Regions
6.5. Oncology Historic and Forecast Sales By Regions
6.6. CNS Condition Historic and Forecast Sales By Regions
6.7. Diabetes Historic and Forecast Sales By Regions
6.8. Obesity Historic and Forecast Sales By Regions
6.9. Cardiovascular Historic and Forecast Sales By Regions
6.10. Others Historic and Forecast Sales By Regions

7. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY INDICATION

7.1. Overview By Indication
7.2. Historical and Forecast Data Analysis By Indication
7.3. Autoimmune/Inflammation (Rheumatoid arthritis, Multiple Sclerosis, Osteoarthritis, Irritable Bowel Syndrome (IBS), Others) Historic and Forecast Sales By Regions
7.4. Pain Management (Chronic Pain, Acute Pain) Historic and Forecast Sales By Regions
7.5. Oncology (Blood Cancer, Solid Tumors, Other) Historic and Forecast Sales By Regions
7.6. CNS Condition (Epilepsy, Parkinson's Disease (PD), Huntington's Disease, Stroke, Traumatic Brain Injury (TBI), Amyotrophic Lateral Sclerosis (ALS), Muscle Regeneration, Others) Historic and Forecast Sales By Regions
7.7. Diabetes Historic and Forecast Sales By Regions
7.8. Obesity Historic and Forecast Sales By Regions
7.9. Cardiovascular Historic and Forecast Sales By Regions
7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY SPONSOR

8.1. Overview By Sponsor
8.2. Historical and Forecast Data Analysis By Sponsor
8.3. Pharmaceutical & Biopharmaceutical Companies Historic and Forecast Sales By Regions
8.4. Medical Device Companies Historic and Forecast Sales By Regions
8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY SERVICE TYPE

9.1. Overview By Service Type
9.2. Historical and Forecast Data Analysis By Service Type
9.3. Protocol Designing Historic and Forecast Sales By Regions
9.4. Site Identification Historic and Forecast Sales By Regions
9.5. Patient Recruitment Historic and Forecast Sales By Regions
9.6. Laboratory Services Historic and Forecast Sales By Regions
9.7. Bioanalytical Testing Services Historic and Forecast Sales By Regions
9.8. Clinical Trial Data Management Services Historic and Forecast Sales By Regions
9.9. Others Historic and Forecast Sales By Regions

10. GLOBAL CLINICAL TRIALS MARKET ANALYSIS BY GEOGRAPHY

10.1. Regional Outlook
10.2. Introduction
10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis

11. COMPETITIVE LANDSCAPE OF THE CLINICAL TRIALS COMPANIES

11.1. Clinical Trials Market Competition
11.2. Partnership/Collaboration/Agreement
11.3. Merger And Acquisitions
11.4. New Product Launch
11.5. Other Developments

12. COMPANY PROFILES OF CLINICAL TRIALS INDUSTRY

12.1. Top Companies Market Share Analysis
12.2. Market Concentration Rate
12.3. Pharmaceutical Product Development Inc. (Thermo Fisher Scientific Inc.)
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
12.4. ICON Plc
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
12.5. Charles River Laboratories International Inc.
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
12.6. IQVIA
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
12.7. Syneos Health
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
12.8. SGS SA
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
12.9. Parexel International Corporation
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
12.10. Wuxi AppTec Inc
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
12.11. Chiltern International Ltd (Laboratory Corporation Of America)
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
12.12. Eli Lilly And Company
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
12.13. Novo Nordisk A/S
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
12.14. Pfizer
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
12.15. Clinipace (Caidya)
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies